Navigation Links
Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
Date:10/5/2009

CLEARWATER, Fla., Oct. 5 /PRNewswire-FirstCall/ -- Lincare Holdings Inc. (Nasdaq: LNCR) today announced that it has extended the terms of the employment agreements with its Chief Executive Officer, John P. Byrnes, its President and Chief Operating Officer, Shawn S. Schabel and its Chief Financial Officer, Paul G. Gabos. The agreements provide for the continuation of each executive officer's employment with the company for three additional years through December 31, 2012. The employment agreements amend the previous agreements that were set to expire on December 31, 2009.

Lincare, headquartered in Clearwater, Florida, is one of the nation's largest providers of respiratory therapy and other services to patients in the home. The Company provides services and equipment to more than 700,000 customers in 48 states.

Statements in this release concerning future results, performance or expectations are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All forward-looking statements included in this document are based upon information available to Lincare as of the date hereof and Lincare assumes no obligation to update any such forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause Lincare's actual results, levels of activity, performance or achievements to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statements. In some cases, forward-looking statements that involve risks and uncertainties contain terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or variations of these terms or other comparable terminology.

Key factors that have an impact on Lincare's ability to attain any estimates contained in this release include potential reductions in reimbursement rates by government and other third party payors, changes in reimbursement policies, the demand for Lincare's products and services, the availability of appropriate acquisition candidates and Lincare's ability to successfully complete and integrate acquisitions, efficient operation of Lincare's existing and future operating facilities, regulation and/or regulatory action affecting Lincare or its business, economic and competitive conditions, access to borrowed and/or equity capital on favorable terms and other risks described in the filings of Lincare with the Securities and Exchange Commission.

In developing its forward-looking statements, Lincare has made certain assumptions relating to reimbursement rates and policies, internal growth and acquisitions and the outcome of various legal and regulatory proceedings. If the assumptions used by Lincare differ materially from what actually occurs, then actual results could vary significantly from the performance projected in the forward-looking statements. Lincare is under no duty to update any of the forward-looking statements after the date of this release.

SOURCE Lincare Holdings Inc.


'/>"/>
SOURCE Lincare Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2009 Results
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
6. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
7. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
11. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is teaming up ... Technologies Limited to lower diabetes healthcare costs in ... card, which is available throughout all provinces and territories ... be eligible for additional savings when shopping for Dario ...
(Date:5/3/2017)... COUNTY, Calif. , May 3, 2017 /PRNewswire/ ... aspect of any hospital or healthcare facility. Commonly ... examination room is equipped with diagnostic imaging technology ... arteries of the heart. In these spaces, a ... angiography, catheterization, balloon angioplasty, percutaneous coronary intervention, congenital ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon on ... importance of prostate cancer screenings. Early detection of the disease, he says, can make ... at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate ...
(Date:5/19/2017)... ... , ... CloSYS products which are marketed as the gentle giants of the ... gum health, which is linked to one’s overall health. Since 1991 when the CloSYS ... ways in which CloSYS products immediately helped eliminate bad breath as well as help ...
(Date:5/19/2017)... Santa Clara, CA (PRWEB) , ... May 18, 2017 , ... ... feature that allows sleep labs and physicians to independently dispense CPAP devices and supplies, ... DME orders, and sleep labs can dispense the devices. Device registration for daily usage ...
(Date:5/18/2017)... ... May 18, 2017 , ... Originally launched to market as the EPIK ... Due to the rapid expansion of their product line, the company believed it was ... Now, the HighQ brand will be any tablet product sold by EPIK Learning. ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... Alliance, a Dulles, VA based educational and charitable organization which sponsors numerous programs ... for their third MURPH Challenge event over Memorial Day Weekend. , The ...
Breaking Medicine News(10 mins):